Pacira Biosciences Inc Financials

PCRX

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

Financial Health Signals

Piotroski F-Score Neutral

4/9

Pacira Biosciences Inc passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass.

Earnings Quality Mixed

-1.90x

For every $1 of reported earnings, Pacira Biosciences Inc generates $-1.90 in operating cash flow ($189.4M OCF vs -$99.6M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Interest Coverage At Risk

-4.4x

Pacira Biosciences Inc earns $-4.4 in operating income for every $1 of interest expense (-$73.4M vs $16.6M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

This page shows Pacira Biosciences Inc (PCRX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Export CSV

Key Financial Metrics

Revenue

N/A

EBITDA

$5.4M

YoY-96.7%

5Y CAGR-29.0%

10Y CAGR+1.1%

Pacira Biosciences Inc's EBITDA was $5.4M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 96.7% from the prior year.

Free Cash Flow

$178.8M

YoY+28.1%

5Y CAGR+24.3%

10Y CAGR+47.9%

Pacira Biosciences Inc generated $178.8M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 28.1% from the prior year.

Net Income

-$99.6M

YoY-337.3%

Pacira Biosciences Inc reported -$99.6M in net income in fiscal year 2024. This represents a decrease of 337.3% from the prior year.

EPS (Diluted)

$-2.15

YoY-341.6%

Pacira Biosciences Inc earned $-2.15 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 341.6% from the prior year.

Cash & Debt

$276.8M

YoY+80.5%

5Y CAGR+28.8%

10Y CAGR+22.1%

Pacira Biosciences Inc held $276.8M in cash against $383.5M in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

46M

YoY-0.5%

5Y CAGR+2.0%

10Y CAGR+2.5%

Pacira Biosciences Inc had 46M shares outstanding in fiscal year 2024. This represents a decrease of 0.5% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

$81.6M

YoY+7.0%

5Y CAGR+2.5%

10Y CAGR+15.9%

Pacira Biosciences Inc invested $81.6M in research and development in fiscal year 2024. This represents an increase of 7.0% from the prior year.

Share Buybacks

$25.0M

Pacira Biosciences Inc spent $25.0M on share buybacks in fiscal year 2024, returning capital to shareholders by reducing shares outstanding.

Capital Expenditures

$10.6M

YoY-29.8%

5Y CAGR+0.9%

10Y CAGR-7.4%

Pacira Biosciences Inc invested $10.6M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 29.8% from the prior year.

PCRX Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	$675.0M+1.2%	$666.8M+23.1%	$541.5M+26.0%	$429.6M+2.0%	$421.0M
Cost of Revenue	$170.4M-7.7%	$184.7M-7.3%	$199.3M+42.1%	$140.3M+19.5%	$117.3M+9.9%	$106.7M
Gross Profit	N/A	$490.3M+4.9%	$467.5M+16.5%	$401.3M+28.5%	$312.3M-0.6%	$314.3M
R&D Expenses	$81.6M+7.0%	$76.3M-10.1%	$84.8M+52.7%	$55.5M-6.5%	$59.4M-17.6%	$72.1M
SG&A Expenses	$294.1M+9.2%	$269.4M+5.9%	$254.5M+27.7%	$199.3M+3.0%	$193.5M-3.6%	$200.8M
Operating Income	-$73.4M-183.7%	$87.7M+46.1%	$60.0M-33.3%	$89.9M+94.0%	$46.4M+342.3%	$10.5M
Interest Expense	$16.6M-18.4%	$20.3M-49.2%	$40.0M+25.9%	$31.8M+23.7%	$25.7M+8.6%	$23.6M
Income Tax	$36.5M+84.6%	$19.7M+857.4%	-$2.6M-118.1%	$14.4M+111.5%	-$125.4M-46903.7%	$268K
Net Income	-$99.6M-337.3%	$42.0M+163.7%	$15.9M-62.1%	$42.0M-71.2%	$145.5M+1421.0%	-$11.0M
EPS (Diluted)	$-2.15-341.6%	$0.89+161.8%	$0.34-63.0%	$0.92-72.4%	$3.33+1333.3%	$-0.27

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Revenue	$179.5M-0.9%	$181.1M+7.2%	$168.9M+0.2%	$168.6M-5.3%	$178.0M+6.5%	$167.1M-7.8%	$181.2M+10.6%	$163.9M
Cost of Revenue	$34.3M-16.1%	$40.9M+19.1%	$34.3M-11.7%	$38.9M-12.2%	$44.3M-6.7%	$47.4M-0.6%	$47.7M+20.0%	$39.8M
Gross Profit	$145.2M+3.6%	$140.2M+4.2%	$134.6M+3.8%	$129.7M-3.0%	$133.8M+11.7%	$119.7M-10.4%	$133.6M+7.6%	$124.2M
R&D Expenses	$26.0M-7.9%	$28.2M+11.3%	$25.3M+32.7%	$19.1M-6.1%	$20.3M+11.5%	$18.2M-6.3%	$19.5M-6.6%	$20.8M
SG&A Expenses	$91.8M+3.6%	$88.6M+2.1%	$86.8M+16.7%	$74.3M+9.1%	$68.1M-5.4%	$72.0M+9.5%	$65.8M-3.2%	$67.9M
Operating Income	$6.4M-25.1%	$8.5M+327.1%	$2.0M+101.4%	-$139.5M-594.1%	$28.2M+113.7%	$13.2M-60.2%	$33.2M+87.2%	$17.7M
Interest Expense	$4.3M-8.9%	$4.7M+2.5%	$4.6M-2.3%	$4.7M+20.7%	$3.9M+17.1%	$3.3M-2.1%	$3.4M-2.2%	$3.5M
Income Tax	$4.1M+40.1%	$2.9M-25.0%	$3.9M-15.5%	$4.6M-74.0%	$17.7M+279.7%	$4.7M-47.3%	$8.8M+54.1%	$5.7M
Net Income	$5.4M+212.1%	-$4.8M-200.7%	$4.8M+103.4%	-$143.5M-859.6%	$18.9M+110.3%	$9.0M-63.9%	$24.9M+129.0%	$10.9M
EPS (Diluted)	$0.12+209.1%	$-0.11-210.0%	$0.10+103.2%	$-3.11-897.4%	$0.39+105.3%	$0.19-67.2%	$0.58+152.2%	$0.23

PCRX Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$1.6B-1.3%	$1.6B-6.4%	$1.7B-19.0%	$2.1B+62.8%	$1.3B+53.4%	$831.1M
Current Assets	$745.1M+46.1%	$510.0M+2.3%	$498.3M-42.5%	$866.0M+32.9%	$651.6M+59.5%	$408.6M
Cash & Equivalents	$276.8M+80.5%	$153.3M+47.2%	$104.1M-82.2%	$585.6M+485.8%	$100.0M+27.8%	$78.2M
Inventory	$125.3M+20.1%	$104.4M+8.6%	$96.1M-2.5%	$98.5M+52.4%	$64.7M+10.9%	$58.3M
Accounts Receivable	$113.3M+7.3%	$105.6M+7.3%	$98.4M+2.2%	$96.3M+81.6%	$53.0M+11.6%	$47.5M
Goodwill	$0-100.0%	$163.2M0.0%	$163.2M+12.4%	$145.2M+45.9%	$99.5M0.0%	$99.5M
Total Liabilities	$775.2M+10.1%	$704.3M-22.3%	$906.2M-32.6%	$1.3B+105.4%	$654.8M+37.5%	$476.1M
Current Liabilities	$309.9M+218.2%	$97.4M-34.1%	$147.8M-71.6%	$521.1M+105.7%	$253.3M+135.3%	$107.7M
Long-Term Debt	$383.5M-26.6%	$522.4M-24.2%	$689.5M	N/A	N/A	N/A
Total Equity	$778.3M-10.5%	$870.1M+12.3%	$775.0M+6.1%	$730.4M+17.9%	$619.7M+74.6%	$354.9M
Retained Earnings	-$206.4M-93.2%	-$106.8M+28.2%	-$148.8M+29.8%	-$211.9M+16.5%	-$253.9M+36.4%	-$399.4M

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Total Assets	$1.3B-15.6%	$1.5B-3.1%	$1.6B+2.1%	$1.6B-5.7%	$1.6B+4.0%	$1.6B+0.6%	$1.6B+2.6%	$1.5B
Current Assets	$562.8M-24.5%	$745.6M-1.9%	$760.0M+2.0%	$745.1M+17.9%	$632.2M+16.4%	$543.1M+6.5%	$510.0M+14.0%	$447.3M
Cash & Equivalents	$147.6M-50.9%	$300.5M+5.9%	$283.6M+2.5%	$276.8M+12.0%	$247.1M+34.2%	$184.1M+20.1%	$153.3M+54.7%	$99.1M
Inventory	$157.7M+6.4%	$148.2M+10.8%	$133.8M+6.8%	$125.3M+21.1%	$103.4M+6.9%	$96.8M-7.3%	$104.4M+8.1%	$96.5M
Accounts Receivable	$115.3M+0.8%	$114.4M+9.2%	$104.7M-7.6%	$113.3M+8.1%	$104.8M+3.1%	$101.6M-3.7%	$105.6M+8.9%	$97.0M
Goodwill	$20.3M+0.1%	$20.3M-5.7%	$21.5M	$0-100.0%	$163.2M0.0%	$163.2M0.0%	$163.2M0.0%	$163.2M
Total Liabilities	$570.4M-26.8%	$779.5M-1.1%	$788.1M+1.7%	$775.2M+1.0%	$767.5M+11.1%	$691.2M-1.9%	$704.3M+0.2%	$702.9M
Current Liabilities	$107.1M-65.8%	$313.2M-0.5%	$314.7M+1.6%	$309.9M+234.4%	$92.7M-0.8%	$93.4M-4.0%	$97.4M+4.0%	$93.7M
Long-Term Debt	$376.7M-35.1%	$580.5M-0.5%	$583.4M+52.1%	$383.5M	N/A	N/A	$522.4M	N/A
Total Equity	$727.2M-4.0%	$757.8M-5.1%	$798.5M+2.6%	$778.3M-11.5%	$879.3M-1.4%	$892.2M+2.5%	$870.1M+4.6%	$831.6M
Retained Earnings	-$201.0M+2.6%	-$206.4M-2.4%	-$201.5M+2.3%	-$206.4M-161.4%	-$78.9M+19.3%	-$97.8M+8.4%	-$106.8M+18.9%	-$131.7M

PCRX Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	$189.4M+22.5%	$154.6M+6.5%	$145.3M+15.6%	$125.7M+63.2%	$77.0M+9.2%	$70.5M
Capital Expenditures	$10.6M-29.8%	$15.2M-49.6%	$30.1M-34.4%	$45.9M+21.3%	$37.8M+272.1%	$10.2M
Free Cash Flow	$178.8M+28.1%	$139.5M+21.1%	$115.2M+44.3%	$79.9M+103.5%	$39.2M-35.0%	$60.4M
Investing Cash Flow	-$83.3M-207.4%	$77.5M+134.4%	-$225.2M-983.1%	-$20.8M+92.5%	-$277.6M-116.1%	-$128.5M
Financing Cash Flow	$17.4M+109.5%	-$183.0M+54.4%	-$401.5M-205.5%	$380.7M+71.2%	$222.3M+5957.3%	$3.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$25.0M	$0	$0	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Operating Cash Flow	$60.8M+406.4%	$12.0M-66.1%	$35.5M+7.0%	$33.1M-37.8%	$53.2M+8.4%	$49.1M+3.2%	$47.6M+7.1%	$44.4M
Capital Expenditures	$3.9M+43.5%	$2.7M-68.4%	$8.5M+303.6%	$2.1M+33.2%	$1.6M-43.9%	$2.8M+57.7%	$1.8M-47.0%	$3.4M
Free Cash Flow	$57.0M+511.5%	$9.3M-65.4%	$26.9M-13.2%	$31.0M-39.9%	$51.6M+11.6%	$46.3M+1.0%	$45.8M+11.6%	$41.0M
Investing Cash Flow	$43.6M-29.8%	$62.2M+342.5%	-$25.6M-6864.4%	-$368K+97.6%	-$15.2M+2.0%	-$15.5M-285.5%	$8.4M+292.9%	-$4.3M
Financing Cash Flow	-$257.5M-347.7%	-$57.5M-1820.7%	-$3.0M-53.1%	-$2.0M-107.8%	$25.0M+986.8%	-$2.8M-58.3%	-$1.8M+93.6%	-$27.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$50.0M	N/A	N/A	$0	N/A	N/A	$0	$0

PCRX Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	72.6%+2.5pp	70.1%-4.0pp	74.1%+1.4pp	72.7%-2.0pp	74.7%
Operating Margin	N/A	13.0%+4.0pp	9.0%-7.6pp	16.6%+5.8pp	10.8%+8.3pp	2.5%
Net Margin	N/A	6.2%+3.8pp	2.4%-5.4pp	7.8%-26.1pp	33.9%+36.5pp	-2.6%
Return on Equity	N/A	4.8%+2.8pp	2.1%-3.7pp	5.8%-17.7pp	23.5%	N/A
Return on Assets	-6.4%-9.1pp	2.7%+1.7pp	0.9%-1.1pp	2.0%-9.4pp	11.4%+12.8pp	-1.3%
Current Ratio	2.40-2.8	5.24+1.9	3.37+1.7	1.66-0.9	2.57-1.2	3.79
Debt-to-Equity	0.49-0.1	0.60-0.3	0.89-1.0	1.84+0.8	1.06-0.3	1.34
FCF Margin	N/A	20.7%+3.4pp	17.3%+2.5pp	14.8%+5.6pp	9.1%-5.2pp	14.3%

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Gross Margin	80.9%+3.5pp	77.4%-2.3pp	79.7%+2.7pp	77.0%+1.8pp	75.1%+3.5pp	71.6%-2.1pp	73.7%-2.1pp	75.8%
Operating Margin	3.5%-1.1pp	4.7%+3.5pp	1.2%+84.0pp	-82.8%-98.6pp	15.9%+7.9pp	7.9%-10.4pp	18.3%+7.5pp	10.8%
Net Margin	3.0%+5.7pp	-2.7%-5.5pp	2.9%+88.0pp	-85.1%-95.7pp	10.6%+5.2pp	5.4%-8.3pp	13.7%+7.1pp	6.6%
Return on Equity	0.8%	N/A	0.6%	N/A	2.1%+1.1pp	1.0%-1.9pp	2.9%+1.6pp	1.3%
Return on Assets	0.4%+0.7pp	-0.3%-0.6pp	0.3%+9.7pp	-9.4%-10.6pp	1.1%+0.6pp	0.6%-1.0pp	1.6%+0.9pp	0.7%
Current Ratio	5.26+2.9	2.38-0.0	2.41+0.0	2.40-4.4	6.82+1.0	5.81+0.6	5.24+0.5	4.78
Debt-to-Equity	0.52-0.2	0.77+0.0	0.73+0.2	0.49-0.4	0.87+0.1	0.77+0.2	0.60-0.2	0.85
FCF Margin	31.7%+26.6pp	5.1%-10.8pp	15.9%-13.6pp	29.6%+0.5pp	29.0%+1.3pp	27.7%+2.4pp	25.3%+0.2pp	25.0%

Similar Companies

Collegium Pharmaceutical Inc COLL

$1.4B

Dynavax Technolo DVAX

$1.8B

Avadel Pharmaceu AVDL

$2.1B

Harrow Health Inc HROW

$1.7B

Amphastar Pharma AMPH

$1.3B

Frequently Asked Questions

Is Pacira Biosciences Inc profitable?

No, Pacira Biosciences Inc (PCRX) reported a net income of -$99.6M in fiscal year 2024.

What is Pacira Biosciences Inc's earnings per share (EPS)?

Pacira Biosciences Inc (PCRX) reported diluted earnings per share of $-2.15 for fiscal year 2024. This represents a -341.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Pacira Biosciences Inc's EBITDA?

Pacira Biosciences Inc (PCRX) had EBITDA of $5.4M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Pacira Biosciences Inc have?

As of fiscal year 2024, Pacira Biosciences Inc (PCRX) had $276.8M in cash and equivalents against $383.5M in long-term debt.

What is Pacira Biosciences Inc's free cash flow?

Pacira Biosciences Inc (PCRX) generated $178.8M in free cash flow during fiscal year 2024. This represents a 28.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Pacira Biosciences Inc's operating cash flow?

Pacira Biosciences Inc (PCRX) generated $189.4M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Pacira Biosciences Inc's total assets?

Pacira Biosciences Inc (PCRX) had $1.6B in total assets as of fiscal year 2024, including both current and long-term assets.

What are Pacira Biosciences Inc's capital expenditures?

Pacira Biosciences Inc (PCRX) invested $10.6M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Pacira Biosciences Inc spend on research and development?

Pacira Biosciences Inc (PCRX) invested $81.6M in research and development during fiscal year 2024.

Does Pacira Biosciences Inc buy back shares?

Yes, Pacira Biosciences Inc (PCRX) spent $25.0M on share buybacks during fiscal year 2024, returning capital to shareholders by reducing shares outstanding.

How many shares does Pacira Biosciences Inc have outstanding?

Pacira Biosciences Inc (PCRX) had 46M shares outstanding as of fiscal year 2024.

What is Pacira Biosciences Inc's current ratio?

Pacira Biosciences Inc (PCRX) had a current ratio of 2.40 as of fiscal year 2024, which is generally considered healthy.

What is Pacira Biosciences Inc's debt-to-equity ratio?

Pacira Biosciences Inc (PCRX) had a debt-to-equity ratio of 0.49 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Pacira Biosciences Inc's return on assets (ROA)?

Pacira Biosciences Inc (PCRX) had a return on assets of -6.4% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Pacira Biosciences Inc's Piotroski F-Score?

Pacira Biosciences Inc (PCRX) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Pacira Biosciences Inc's earnings high quality?

Pacira Biosciences Inc (PCRX) has an earnings quality ratio of -1.90x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Pacira Biosciences Inc cover its interest payments?

Pacira Biosciences Inc (PCRX) has an interest coverage ratio of -4.4x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.